You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康臣藥業(01681.HK)與倍特藥業簽署戰略合作協議及項目協議
格隆匯 07-23 20:38

格隆匯7月23日丨康臣藥業(01681.HK)宣佈,公司全資附屬公司廣州康臣藥業有限公司("廣州康臣")於2021年6月28日(i)與成都倍特藥業股份有限公司("倍特藥業")就造影劑領域的戰略合作訂立一項戰略合作協議;及(ii)與倍特藥業及其全資附屬公司四川仁安藥業有限責任公司("仁安藥業")訂立一項有關某型碘劑項目三方合作協議。

根據戰略合作協議,廣州康臣和倍特藥業希望在造影劑系列產品的原料藥和製劑研發申報、及市場開發方面進行合作。在生產階段,廣州康臣將負責生產造影劑製劑,仁安藥業將成為廣州康臣造影劑原料藥的首選供應商。

項目協議的合作內容為:由倍特藥業開展某型碘造影劑製劑的研發工作,並協助廣州康臣完成該型碘造影劑製劑相關的申報和註冊;廣州康臣生產該型碘造影劑製劑時,在同等條件下優先使用仁安藥業生產的原料藥;仁安藥業保證產品質量,穩定供貨,並且該型碘造影劑製劑銷售價格調整時,仁安藥業供應的原料藥價格應相應調整,使廣州康臣及仁安藥業雙方均可獲得行業內合理的利潤。項目協議形成的全部數據、所提交的研究報吿以及與生產工藝相關的技術文件歸廣州康臣所有。

公吿稱,與倍特藥業的戰略合作以及項目協議下各方的合作將增強集團在化學藥品原料藥方面的供應和保障,同時增強和擴大集團在造影劑(碘注射液和釓注射液)的研發覆蓋範圍,同時,此次戰略合作以及項目協議下各方的合作符合造影劑"原料藥+製劑"一體化的未來發展趨勢。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account